[18F]TM-30089 underwent systematic evaluation in both mouse models implanted with 1.1 B4 (GPR44-enriched tumor cell line) and transplanted human islets (GPR44 high expression), demonstrating its potential for specific GPR44 targeting. Here, PTGDR2 is linked to neoplasm.